Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
1. Bristol Myers Squibb's Cobenfy targets Alzheimer's-related psychosis, a significant market. 2. Cobenfy could generate peak sales of up to $10 billion across multiple uses. 3. Initial late-stage trial data for Cobenfy will be released earlier than expected. 4. Cobenfy addresses risks of atypical antipsychotics, offering a safer alternative. 5. 6 million Alzheimer’s patients in the U.S. amplify Cobenfy's market potential.